| Literature DB >> 29605494 |
Abdulkerim Eroglu1, Kerry J Schulze2, James Yager3, Robert N Cole4, Parul Christian2, Bareng A S Nonyane2, Sun Eun Lee2, Lee S F Wu2, Subarna Khatry2, John Groopman3, Keith P West2.
Abstract
Carotenoids are naturally occurring pigments that function as vitamin A precursors, antioxidants, anti-inflammatory agents or biomarkers of recent vegetable and fruit intake, and are thus important for population health and nutritional assessment. An assay approach that measures proteins could be more technologically feasible than chromatography, thus enabling more frequent carotenoid status assessment. We explored associations between proteomic biomarkers and concentrations of 6 common dietary carotenoids (α-carotene, β-carotene, lutein/zeaxanthin, β-cryptoxanthin, and lycopene) in plasma from 500 6-8 year old Nepalese children. Samples were depleted of 6 high-abundance proteins. Plasma proteins were quantified using tandem mass spectrometry and expressed as relative abundance. Linear mixed effects models were used to determine the carotenoid:protein associations, accepting a false discovery rate of q < 0.10. We quantified 982 plasma proteins in >10% of all child samples. Among these, relative abundance of 4 were associated with β-carotene, 11 with lutein/zeaxanthin and 51 with β-cryptoxanthin. Carotenoid-associated proteins are notably involved in lipid and vitamin A transport, antioxidant function and anti-inflammatory processes. No protein biomarkers met criteria for association with α-carotene or lycopene. Plasma proteomics may offer an approach to assess functional biomarkers of carotenoid status, intake and biological function for public health application. Original maternal micronutrient trial from which data were derived as a follow-up activity was registered at ClinicalTrials.gov: NCT00115271.Entities:
Keywords: Antioxidants; Carotenoids; Nepal; Plasma proteins; Proteomics; β-cryptoxanthin
Mesh:
Substances:
Year: 2018 PMID: 29605494 PMCID: PMC5937903 DOI: 10.1016/j.abb.2018.03.025
Source DB: PubMed Journal: Arch Biochem Biophys ISSN: 0003-9861 Impact factor: 4.013
Plasma carotenoid concentrations (μmol/L) of children, 6–8 years of age, Sarlahi, Nepal.
| Plasma carotenoids | n | Median (IQR) |
|---|---|---|
| β-Carotene | 497 | 0.10 (0.06, 0.19) |
| Lutein/zeaxanthin | 500 | 0.34 (0.25, 0.48) |
| β-Cryptoxanthin | 500 | 0.06 (0.04, 0.12) |
| α-Carotene | 481 | 0.01 (0.01, 0.02) |
| Lycopene | 171 | 0.02 (0.01, 0.03) |
n represents the number of samples with detectable concentration of each carotenoid.
IQR = interquartile range.
Cutoff for low plasma β-carotene is 0.09 μmol/L, below which 207 values were observed (41.6%).
Fig. 1Correlations between plasma carotenoids in 6–8 year old children of rural Nepal. Correlation coefficients were generated using all complete pairwise data. All of the correlations were statistically significant (p < 0.0001) except log2 β-carotene with log2 α-carotene (p = 0.56), log2 β-carotene with log2 lycopene (p = 0.96) and log2 α-carotene with log2 lycopene (p = 0.0786).
Plasma proteins associated with plasma log2 β-carotene in 6–8 year old children of rural Nepal (n = 497).a
| Gene Name | Gene Symbol | gi Accession Number | ||||||
|---|---|---|---|---|---|---|---|---|
| Orosomucoid 1 | 497 | −0.7 | 0.49 | 6.07 × 10−5 | 2.60 × 10−2 | −33.0 | ||
| Apolipoprotein A-I | 497 | 0.7 | 0.49 | 6.28 × 10−5 | 2.60 × 10−2 | 94.1 | ||
| Pyruvate kinase, muscle | 55 | −0.65 | 0.42 | 1.78 × 10−4 | 4.94 × 10−2 | −67.7 | ||
| TNFAIP3 interacting protein 1 | 385 | −0.69 | 0.48 | 1.79 × 10−4 | 4.94 × 10−2 | −35.6 |
Four proteins quantified by mass spectrometry and estimated by linear mixed effects (LME) modelling in >10% of the samples (50 < n ≤ 497) that are correlated with plasma log2 β-carotene, subjected to a false discovery rate (FDR) cutoff of 10% (q < 0.10), and listed in increasing order of q, defined as candidate protein biomarkers for a plasma β-carotene proteome.
n represents the number of child plasma samples in which a protein was detected and quantified by iTRAQ MS.
b represents the percent change in plasma β-carotene, (in μmol/L) per 2-fold (100%) increase in protein relative abundance.
GenInfo Identifier sequence number, as assigned to all nucleotide and protein sequences by the National Center for Biotechnology Information at the National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
Plasma proteins associated with plasma log2 lutein/zeaxanthin in 6–8 year old children of rural Nepal (n = 500).a
| Gene Name | Gene Symbol | gi Accession Number | ||||||
|---|---|---|---|---|---|---|---|---|
| Apolipoprotein C-III | 500 | 0.59 | 0.34 | 9.15 × 10−5 | 5.12 × 10−2 | 25.4 | ||
| Inter-alpha-trypsin inhibitor heavy chain 3 | 500 | −0.58 | 0.34 | 1.21 × 10−4 | 5.12 × 10−2 | −28.2 | ||
| Heat shock 70 kDa protein 1A | 119 | 0.51 | 0.26 | 1.61 × 10−4 | 5.43 × 10−2 | 69.9 | ||
| Collagen, type V, alpha 1 | 56 | 0.59 | 0.35 | 3.57 × 10−4 | 8.40 × 10−2 | 101.3 | ||
| Minichromosome maintenance complex component 2 | 119 | −0.64 | 0.41 | 4.95 × 10−4 | 8.40 × 10−2 | −31.8 | ||
| TNFAIP3 interacting protein 1 | 388 | −0.6 | 0.36 | 5.43 × 10−4 | 8.40 × 10−2 | −22.4 | ||
| CD14 molecule | 500 | −0.58 | 0.34 | 5.57 × 10−4 | 8.40 × 10−2 | −37.7 | ||
| Carnosine dipeptidase 1 (metallopeptidase M20 family) | 500 | 0.58 | 0.34 | 6.12 × 10−4 | 8.40 × 10−2 | 16.8 | ||
| Interferon-related developmental regulator 2 | 486 | 0.59 | 0.35 | 6.47 × 10−4 | 8.40 × 10−2 | 27.8 | ||
| Apolipoprotein A-I | 500 | 0.58 | 0.34 | 6.48 × 10−4 | 8.40 × 10−2 | 43.3 | ||
| Proteoglycan 4 | 403 | 0.6 | 0.36 | 7.84 × 10−4 | 9.44 × 10−2 | 46.7 |
Eleven proteins quantified by mass spectrometry and estimated by linear mixed effects (LME) modelling in >10% of the samples (50 < n ≤ 500) that are correlated with plasma log2 lutein/zeaxanthin, subjected to a false discovery rate (FDR) cutoff of 10% (q < 0.10), and listed in increasing order of q, defined as candidate protein biomarkers for a plasma proteome of lutein/zeaxanthin.
n represents the number of child plasma samples in which a protein was detected and quantified by iTRAQ MS.
b represents the percent change in plasma lutein/zeaxanthin, (in μmol/L) per 2-fold (100%) increase in protein relative abundance.
GenInfo Identifier sequence number, as assigned to all nucleotide and protein sequences by the National Center for Biotechnology Information at the National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
Plasma proteins positively associated with plasma log2 β-cryptoxanthin in 6–8 year old children of rural Nepal (n = 500).a
| Gene Name | Gene Symbol | gi Accession Number | ||||||
|---|---|---|---|---|---|---|---|---|
| Apolipoprotein A-I | 500 | 0.52 | 0.27 | 5.27 × 10−9 | 7.95 × 10−6 | 193.1 | ||
| Interferon-related developmental regulator 2 | 486 | 0.51 | 0.26 | 1.33 × 10−7 | 1.00 × 10−4 | 99.4 | ||
| Carnosine dipeptidase 1 (metallopeptidase M20 family) | 500 | 0.50 | 0.25 | 5.41 × 10−6 | 1.63 × 10−3 | 44.0 | ||
| Apolipoprotein C-III | 500 | 0.50 | 0.25 | 8.47 × 10−6 | 2.13 × 10−3 | 58.1 | ||
| Phospholipid transfer protein | 472 | 0.49 | 0.24 | 1.09 × 10−5 | 2.36 × 10−3 | 133.7 | ||
| PILR alpha associated neural protein | 360 | 0.49 | 0.24 | 1.85 × 10−5 | 3.49 × 10−3 | 191.8 | ||
| Anthrax toxin receptor 2 | 367 | 0.53 | 0.28 | 2.11 × 10−5 | 3.53 × 10−3 | 95.5 | ||
| Selenoprotein P, plasma, 1 | 500 | 0.50 | 0.25 | 2.69 × 10−5 | 4.06 × 10−3 | 96.7 | ||
| Clusterin | 493 | 0.50 | 0.25 | 5.73 × 10−5 | 7.20 × 10−3 | 300.1 | ||
| Insulin-like growth factor binding protein, acid labile subunit | 500 | 0.49 | 0.24 | 8.82 × 10−5 | 8.87 × 10−3 | 71.2 | ||
| Protein phosphatase, Mg2+/Mn2+ dependent, 1 M | 98 | 0.57 | 0.33 | 1.24 × 10−4 | 1.17 × 10−2 | 14.2 | ||
| Apolipoprotein A-II | 500 | 0.49 | 0.24 | 1.52 × 10−4 | 1.35 × 10−2 | 90.4 | ||
| Paraoxonase 1 | 500 | 0.49 | 0.24 | 2.03 × 10−4 | 1.51 × 10−2 | 61.5 | ||
| Lymphatic vessel endothelial hyaluronan receptor 1 | 479 | 0.5 | 0.25 | 2.10 × 10−4 | 1.51 × 10−2 | 64.4 | ||
| Retinol binding protein 4, plasma | 500 | 0.49 | 0.24 | 2.80 × 10−4 | 1.69 × 10−2 | 75.6 | ||
| Eukaryotic translation initiation factor 2D | 256 | 0.52 | 0.27 | 3.31 × 10−4 | 1.82 × 10−2 | 82.1 | ||
| Apolipoprotein D | 500 | 0.49 | 0.24 | 3.38 × 10−4 | 1.82 × 10−2 | 71.5 | ||
| Kelch-like family member 34 | 403 | 0.51 | 0.26 | 3.90 × 10−4 | 2.03 × 10−2 | 90.3 | ||
| Kruppel-like factor 17 | 284 | 0.51 | 0.26 | 4.69 × 10−4 | 2.36 × 10−2 | 52.5 | ||
| Prenylcysteine oxidase 1 | 493 | 0.48 | 0.23 | 5.48 × 10−4 | 2.43 × 10−2 | 68.4 | ||
| Gelsolin | 493 | 0.49 | 0.24 | 5.93 × 10−4 | 2.47 × 10−2 | 92.5 | ||
| Thrombospondin 4 | 451 | 0.5 | 0.25 | 6.08 × 10−4 | 2.47 × 10−2 | 49.5 | ||
| Apolipoprotein C-I | 500 | 0.49 | 0.24 | 6.63 × 10−4 | 2.50 × 10−2 | 27.8 | ||
| Dipeptidyl-peptidase 4 | 416 | 0.49 | 0.24 | 7.05 × 10−4 | 2.60 × 10−2 | 94.0 | ||
| Interleukin 1 receptor accessory protein | 321 | 0.48 | 0.23 | 8.68 × 10−4 | 3.05 × 10−2 | 93.5 | ||
| Peptidase inhibitor 16 | 500 | 0.49 | 0.24 | 1.01 × 10−3 | 3.46 × 10−2 | 64.3 | ||
| Lumican | 500 | 0.49 | 0.24 | 1.01 × 10−3 | 3.59 × 10−2 | 86.2 | ||
| Insulin-like growth factor binding protein 3 | 500 | 0.49 | 0.24 | 1.87 × 10−3 | 5.46 × 10−2 | 49.3 | ||
| Cartilage oligomeric matrix protein | 500 | 0.49 | 0.24 | 1.88 × 10−3 | 5.46 × 10−2 | 52.3 | ||
| Glycosylphosphatidylinositol specific phospholipase D1 | 500 | 0.49 | 0.24 | 2.93 × 10−3 | 7.76 × 10−2 | 72.8 | ||
| Nucleolar protein 12 | 228 | 0.52 | 0.27 | 3.39 × 10−3 | 8.53 × 10−2 | 239.9 |
Thirty-one proteins quantified by mass spectrometry and estimated by linear mixed effects (LME) modelling in >10% of the samples that were positively correlated with plasma log2 β-cryptoxanthin (p < 0.01, q < 0.10), listed in increasing order of q, defined as positively associated protein biomarkers of a plasma β-cryptoxanthin.
n represents the number of child plasma samples in which a protein was detected and quantified by iTRAQ tandem MS (excludes subsequent imputations required for multivariable LME models).
b represents the percent change in plasma β-cryptoxanthin (in μmol/L) per 2-fold (100%) increase in protein relative abundance.
GenInfo Identifier sequence number, as assigned to all nucleotide and protein sequences by the National Center for Biotechnology Information at the National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
Plasma proteins negatively associated with plasma log2 β-cryptoxanthin in 6–8 year old children of rural Nepal (n = 500).a
| Gene Name | HUGO Gene Symbol | Accession Number | ||||||
|---|---|---|---|---|---|---|---|---|
| Orosomucoid 1 | 500 | −0.50 | 0.25 | 1.60 × 10−6 | 8.04 × 10−4 | −41.5 | ||
| TNFAIP3 interacting protein 1 | 388 | −0.50 | 0.25 | 2.18 × 10−6 | 8.22 × 10−4 | −46.3 | ||
| Mannosidase, alpha, class 1A, member 1 | 500 | −0.50 | 0.25 | 4.17 × 10−5 | 5.71 × 10−3 | −66.0 | ||
| Haptoglobin | 354 | −0.53 | 0.28 | 6.94 × 10−5 | 8.06 × 10−3 | −13.7 | ||
| Alpha-1-B glycoprotein | 500 | −0.50 | 0.25 | 8.04 × 10−5 | 8.66 × 10−3 | −67.1 | ||
| Haptoglobin-related protein | 431 | −0.52 | 0.27 | 1.83 × 10−4 | 1.51 × 10−2 | −22.0 | ||
| Leucine-rich alpha-2-glycoprotein 1 | 500 | −0.49 | 0.24 | 2.76 × 10−4 | 1.69 × 10−2 | −37.0 | ||
| Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 | 500 | −0.49 | 0.24 | 5.42 × 10−4 | 2.43 × 10−2 | −49.1 | ||
| Orosomucoid 2 | 500 | −0.49 | 0.24 | 6.37 × 10−4 | 2.43 × 10−2 | −41.3 | ||
| Leucine rich repeat containing 47 | 70 | −0.51 | 0.26 | 7.35 × 10−4 | 2.64 × 10−2 | −75.0 | ||
| Complement factor B | 500 | −0.49 | 0.24 | 1.08 × 10−3 | 3.59 × 10−2 | −46.1 | ||
| Beta-2-microglobulin | 493 | −0.49 | 0.24 | 1.28 × 10−3 | 4.10 × 10−2 | −32.7 | ||
| Ecotropic viral integration site 5 | 271 | −0.54 | 0.29 | 1.58 × 10−3 | 4.95 × 10−2 | −34.6 | ||
| Ubiquitin-conjugating enzyme E2L 3 | 144 | −0.33 | 0.11 | 1.68 × 10−3 | 5.18 × 10−2 | −44.2 | ||
| Component of oligomeric golgi complex 3 | 215 | −0.31 | 0.09 | 1.76 × 10−3 | 5.30 × 10−2 | −35.8 | ||
| Lipopolysaccharide binding protein | 500 | −0.49 | 0.24 | 2.09 × 10−3 | 5.73 × 10−2 | −28.4 | ||
| Complement component 9 | 500 | −0.49 | 0.24 | 2.32 × 10−3 | 6.26 × 10−2 | −38.6 | ||
| Inter-alpha-trypsin inhibitor heavy chain family, member 4 | 500 | −0.49 | 0.24 | 3.12 × 10−3 | 8.03 × 10−2 | −58.1 | ||
| Mitogen-activated protein kinase kinase kinase 14 | 307 | −0.50 | 0.25 | 3.14 × 10−3 | 8.03 × 10−2 | −28.4 | ||
| Lysozyme | 493 | −0.49 | 0.24 | 3.74 × 10−3 | 9.25 × 10−2 | −34.6 |
Twenty proteins quantified by mass spectrometry and estimated by linear mixed effects (LME) modelling in >10% of the samples that were negatively correlated with plasma log2 β-cryptoxanthin (p < 0.01, q < 0.10), listed in increasing order of q, defined as negatively associated protein biomarkers of a plasma β-cryptoxanthin.
n represents the number of child plasma samples in which a protein was detected and quantified by iTRAQ MS (excludes subsequent imputations required for multivariable LME models).
b represents the percent change in plasma β-cryptoxanthin (in μmol/L) per 2-fold (100%) increase in protein relative abundance.
GenInfo Identifier sequence number, as assigned to all nucleotide and protein sequences by the National Center for Biotechnology Information at the National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
Fig. 2Matrix of correlation coefficients (r) for pairs of LME-based estimates of relative abundance estimates and plasma log2 β-cryptoxanthin concentration for proteins associated with β-cryptoxanthin, restricted to associations with q < 0.05 (n = 40), in 6–8 year old children of rural Nepal (n = 500). Blue color depicts proteins that share a positive correlation and red color a negative correlation with each other. Darker colors represent stronger association. Correlation coefficients (r) are presented r x 102 to improve visualization given in each cell. APOA2, Apolipoprotein A-II; APOC1, Apolipoprotein C-I; APOD, Apolipoprotein D; B2M, β-2-microglobulin; DPP4, Dipeptidyl-peptidase 4; EIF2D, Eukaryotic translation initiation factor 2D; EVI5, ecotropic viral integration site 5; GSN, gelsolin; IL1RAP, Interleukin 1 receptor accessory protein; KLHL34, Kelch-like family member 34; KLF17, Kruppel-like factor 17; LRG1, leucine-rich α-2-glycoprotein 1; LUM, lumican; PI16, Peptidase inhibitor 16; THBS4, Thrombospondin 4.